Polaris Capital Management LLC Has $133.72 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Polaris Capital Management LLC cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,085,860 shares of the specialty pharmaceutical company’s stock after selling 219,700 shares during the quarter. Jazz Pharmaceuticals comprises about 6.5% of Polaris Capital Management LLC’s investment portfolio, making the stock its 4th biggest holding. Polaris Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $133,724,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of JAZZ. Creative Planning increased its stake in Jazz Pharmaceuticals by 21.7% in the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock worth $408,000 after purchasing an additional 680 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $213,000. GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares in the last quarter. Inspire Investing LLC acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $312,000. Finally, Exchange Traded Concepts LLC boosted its stake in Jazz Pharmaceuticals by 21.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,890 shares of the specialty pharmaceutical company’s stock worth $768,000 after purchasing an additional 1,233 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 2.7 %

JAZZ opened at $123.51 on Tuesday. The company has a market capitalization of $7.47 billion, a P/E ratio of 17.40, a P/E/G ratio of 0.92 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm’s fifty day moving average price is $122.52 and its two-hundred day moving average price is $116.53. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research reports. Needham & Company LLC reissued a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Piper Sandler reiterated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, TD Cowen dropped their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 5,053 shares of company stock worth $617,442. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.